Back to resultsA Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Primary Purpose
Hemodialysis Patients With Hyperphosphatemia
Status
Completed
Phase
Phase 3
Locations
Japan
Study Type
Interventional
Intervention
PA21
Sponsored by
About this trial
This is an interventional treatment trial for Hemodialysis Patients With Hyperphosphatemia focused on measuring Hemodialysis, Hyperphosphatemia
Eligibility Criteria
Inclusion Criteria:
- Receiving stable maintenance hemodialysis 3 times a week.
- Dialysis patients with hyperphosphatemia
Exclusion Criteria:
- Patients having history of a pronounced brain / cardiovascular disorder.
- Patients having severe gastrointestinal disorders.
- Patients having severe hepatic disorders.
Sites / Locations
- JAPAN
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
PA21
Arm Description
Outcomes
Primary Outcome Measures
Incidence of Adverse Events
Secondary Outcome Measures
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
Full Information
NCT ID
NCT01833494
First Posted
April 12, 2013
Last Updated
March 2, 2018
Sponsor
Kissei Pharmaceutical Co., Ltd.
1. Study Identification
Unique Protocol Identification Number
NCT01833494
Brief Title
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Official Title
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Study Type
Interventional
2. Study Status
Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
March 18, 2013 (Actual)
Primary Completion Date
August 2014 (Actual)
Study Completion Date
August 4, 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kissei Pharmaceutical Co., Ltd.
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemodialysis Patients With Hyperphosphatemia
Keywords
Hemodialysis, Hyperphosphatemia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
161 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PA21
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
PA21
Primary Outcome Measure Information:
Title
Incidence of Adverse Events
Time Frame
52 weeks
Secondary Outcome Measure Information:
Title
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
Time Frame
52 weeks
Title
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
Time Frame
52 weeks
Title
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
Time Frame
52 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Receiving stable maintenance hemodialysis 3 times a week.
Dialysis patients with hyperphosphatemia
Exclusion Criteria:
Patients having history of a pronounced brain / cardiovascular disorder.
Patients having severe gastrointestinal disorders.
Patients having severe hepatic disorders.
Facility Information:
Facility Name
JAPAN
City
Multiple Locations
Country
Japan
12. IPD Sharing Statement
Learn more about this trial
A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
We'll reach out to this number within 24 hrs